TNBC, our selected solid tumour indication for its relevant ROR1 prevalence, was in the middle of all 7 haematological tumour types analyzed as a reference point, being significantly lower in ROR1 positivity than CLL and HCL, but higher than in AML and T-NHL. This evidence concerns the gene ROR1 and acute myeloid leukemia.